429 related articles for article (PubMed ID: 27789723)
21. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV.
Trunfio M; Rugge W; Mighetto L; Vai D; Atzori C; Nigra M; Domini S; Borgogno E; Guastamacchia G; Bonora S; Di Perri G; Calcagno A
AIDS; 2020 Nov; 34(13):1899-1906. PubMed ID: 32701580
[TBL] [Abstract][Full Text] [Related]
22. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.
Spudich S; Robertson KR; Bosch RJ; Gandhi RT; Cyktor JC; Mar H; Macatangay BJ; Lalama CM; Rinaldo C; Collier AC; Godfrey C; Eron JJ; McMahon D; Jacobs JL; Koontz D; Hogg E; Vecchio A; Mellors JW
J Clin Invest; 2019 Jul; 129(8):3339-3346. PubMed ID: 31305262
[TBL] [Abstract][Full Text] [Related]
23. Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations.
Oliveira MF; Chaillon A; Nakazawa M; Vargas M; Letendre SL; Strain MC; Ellis RJ; Morris S; Little SJ; Smith DM; Gianella S
PLoS Pathog; 2017 Jan; 13(1):e1006112. PubMed ID: 28046096
[TBL] [Abstract][Full Text] [Related]
24. Analysis of correlation between cerebrospinal fluid and plasma HIV-1 RNA levels in patients with neurological opportunistic diseases.
Christo PP; Greco DB; Aleixo AW; Livramento JA
Rev Inst Med Trop Sao Paulo; 2011; 53(4):193-6. PubMed ID: 21915461
[TBL] [Abstract][Full Text] [Related]
25. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.
Staprans S; Marlowe N; Glidden D; Novakovic-Agopian T; Grant RM; Heyes M; Aweeka F; Deeks S; Price RW
AIDS; 1999 Jun; 13(9):1051-61. PubMed ID: 10397535
[TBL] [Abstract][Full Text] [Related]
26. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
[TBL] [Abstract][Full Text] [Related]
27. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D
Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912
[TBL] [Abstract][Full Text] [Related]
28. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.
De Luca A; Ciancio BC; Larussa D; Murri R; Cingolani A; Rizzo MG; Giancola ML; Ammassari A; Ortona L
Neurology; 2002 Aug; 59(3):342-7. PubMed ID: 12177366
[TBL] [Abstract][Full Text] [Related]
29. Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.
Eggers C; Müller O; Thordsen I; Schreiber M; Methner A
J Neurovirol; 2013 Dec; 19(6):523-30. PubMed ID: 24101298
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
31. Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
Airoldi M; Bandera A; Trabattoni D; Tagliabue B; Arosio B; Soria A; Rainone V; Lapadula G; Annoni G; Clerici M; Gori A
Clin Dev Immunol; 2012; 2012():467154. PubMed ID: 22489249
[TBL] [Abstract][Full Text] [Related]
32. Human pegivirus-1 in the CSF of patients with HIV-associated neurocognitive disorder (HAND) may be derived from blood in highly viraemic patients.
Hardie D; Smuts H
J Clin Virol; 2017 Jun; 91():58-61. PubMed ID: 28499138
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
[TBL] [Abstract][Full Text] [Related]
34. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.
Strain MC; Letendre S; Pillai SK; Russell T; Ignacio CC; Günthard HF; Good B; Smith DM; Wolinsky SM; Furtado M; Marquie-Beck J; Durelle J; Grant I; Richman DD; Marcotte T; McCutchan JA; Ellis RJ; Wong JK
J Virol; 2005 Feb; 79(3):1772-88. PubMed ID: 15650202
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 RNA levels in cerebrospinal fluid and plasma and their correlation with opportunistic neurological diseases in a Brazilian AIDS reference hospital.
Christo PP; Greco DB; Aleixo AW; Livramento JA
Arq Neuropsiquiatr; 2005 Dec; 63(4):907-13. PubMed ID: 16400403
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
Motta I; Allice T; Romito A; Ferrara M; Ecclesia S; Imperiale D; Ghisetti V; Di Perri G; Bonora S; Calcagno A
Antivir Ther; 2017; 22(6):539-543. PubMed ID: 28198350
[TBL] [Abstract][Full Text] [Related]
38. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study.
Hammond ER; Crum RM; Treisman GJ; Mehta SH; Clifford DB; Ellis RJ; Gelman BB; Grant I; Letendre SL; Marra CM; Morgello S; Simpson DM; Mcarthur JC;
J Neurovirol; 2016 Aug; 22(4):479-87. PubMed ID: 26727907
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.
Sinclair E; Ronquillo R; Lollo N; Deeks SG; Hunt P; Yiannoutsos CT; Spudich S; Price RW
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):544-52. PubMed ID: 18362693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
